Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

Phase 3 Completed 611 enrolled Takeda H. Lundbeck A/S · collab

RandomizedParallel-groupDouble-blindTreatment

The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.

Evaluation	Drug	Modality	Dose	Route
Comparator	Duloxetine	Small molecule	60 mg	Oral
Subject	Vortioxetine	Unknown	2.5 mg	Oral
Subject	Vortioxetine	Unknown	5 mg	Oral